---
schema_version: "secwatch.filing_event.v1"
accession: "0001919246-26-000071"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2026-05-14T11:08:04+00:00"
generated_at: "2026-05-14T11:11:37.811631+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pelthos Therapeutics Q1 2026 ZELSUVMI net revenue $10.7M, up 17% QoQ; net loss $10.2M

## Summary
- ZELSUVMI net product revenue $10.7M in Q1 2026, up 17% from $9.1M in Q4 2025; units dispensed 7,884 (+25% QoQ).
- Net loss of $(10.2)M vs $(21.7)M in Q4 2025; adjusted EBITDA $(8.0)M.
- Cash $32.0M as of March 31, 2026; drew $30M from $50M Horizon term loan facility in January 2026.
- Sales force expanded to 64 territory managers from 50; April units 3,776; cumulative >20,000 since July 2025 launch.
- Planned commercialization of XEPI in early 2027 and XEGLYZE in mid-2027.

## SEC filing metadata
- accession: 0001919246-26-000071
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2026-05-14T11:08:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000071/0001919246-26-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000071/pths-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001919246-26-000071
- JSON: https://secwatch.observer/filing/0001919246-26-000071.json
- Plain text: https://secwatch.observer/filing/0001919246-26-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.